Switching to an aromatase inhibitor provides mortality benefit in early breast carcinoma-Reference-Cited by-同舟云学术

Switching to an aromatase inhibitor provides mortality benefit in early breast carcinoma

Published:2007-03-15 Issue:6 Volume:109 Page:1060-1067
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Boccardo Francesco,Rubagotti Alessandra,Aldrighetti Daniela,Buzzi Franco,Cruciani Giorgio,Farris Antonio,Mustacchi Giorgio,Porpiglia Mauro,Schieppati Giorgio,Sismondi Piero

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference25 articles.

1. Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005

2. National Institutes of Health Consensus Development Conference Statement: Adjuvant Therapy for Breast Cancer, November 1-3, 2000

3. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

4. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer

5. A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast Cancer

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effective anti-aromatase therapy to battle against estrogen-mediated breast cancer: Comparative SAR/QSAR assessment on steroidal aromatase inhibitors;European Journal of Medicinal Chemistry;2020-12

2. Onco-Cardiology for Breast Cancer;Breast Disease;2019

3. Onco-cardiology for Breast Cancer;Breast Disease;2016

4. Developing steroidal aromatase inhibitors-an effective armament to win the battle against breast cancer;European Journal of Medicinal Chemistry;2015-11

5. Hormone Receptors and Endocrine Therapy in Breast Cancer;Handbook of Therapeutic Biomarkers in Cancer;2013-06-12